Repealing the Trump Sick Tax Act
- Bill Number
- S. 2447
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-07-24: Read twice and referred to the Committee on Finance.
- Last Updated
- 2025-12-05T22:50:04Z
AI-Generated Summary
Purpose
This bill, S. 2447, aims to undo specific modifications introduced in a prior reconciliation law (Public Law 119-21) related to cost-sharing rules in Medicaid—a federal-state health insurance program for low-income individuals—and exclusions for orphan drugs (medications for rare diseases) in Medicare's Drug Price Negotiation Program, which allows the government to negotiate lower prices for certain prescription drugs covered by Medicare.
Key Provisions
- Short Title: The legislation is named the "Repealing the Trump Sick Tax Act."
- Repeal of Medicaid Cost-Sharing Changes (Section 2): Fully repeals Section 71120 of Public Law 119-21, which altered cost-sharing requirements (the amounts patients must pay out-of-pocket, like copays or deductibles) in Medicaid. Medicaid rules under Title XIX of the Social Security Act will revert to their state before these changes. Additionally, any funds appropriated under that section are canceled (rescinded).
- Repeal of Orphan Drug Exclusions in Medicare (Section 3): Fully repeals Section 71203 of Public Law 119-21, which modified exclusions for orphan drugs from the Medicare Drug Price Negotiation Program. Rules under Title XI of the Social Security Act will revert to their pre-change state, restoring original protections or limits on negotiating prices for these drugs.
Significant Changes to Existing Law
- Reverses amendments from Public Law 119-21 that likely increased patient costs in Medicaid and adjusted how orphan drugs are treated in Medicare negotiations (e.g., possibly removing exemptions that prevented price controls on rare disease treatments).
- Eliminates associated funding from the prior law, effectively restoring the legal framework for Medicaid and Medicare as it existed before 2025 without needing new legislation to implement the reversals.
Potential Impacts
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS), part of the Department of Health and Human Services, would need to update programs and regulations to reflect the pre-2025 rules, potentially reducing administrative burdens but requiring system adjustments. Federal spending could decrease due to rescinded appropriations.
- On Citizens: Medicaid enrollees (often low-income families, children, elderly, and disabled individuals) may see restored lower or no cost-sharing requirements, improving affordability of care. Medicare beneficiaries with rare diseases could benefit from reinstated protections against price negotiations on orphan drugs, potentially maintaining access to treatments without price hikes.
- On International Relations: Minimal direct impact, though changes to U.S. drug pricing could indirectly affect global pharmaceutical markets if they influence drug development incentives.
Main Stakeholders Affected
- Medicaid Beneficiaries: Low-income individuals who rely on the program for healthcare, potentially gaining from reduced out-of-pocket costs.
- Medicare Beneficiaries with Rare Diseases: Patients using orphan drugs, who may retain better access and affordability if exclusions are restored.
- Pharmaceutical Companies: Manufacturers of orphan drugs could see preserved market protections, while broader drug pricing rules might shift negotiation dynamics.
- State Governments: As partners in administering Medicaid, they could face simplified compliance but possible shifts in state-federal funding balances.
- Federal Government: Agencies like CMS and the Department of Health and Human Services would implement changes, affecting healthcare budgets.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill uses repeal mechanisms to nullify prior amendments without creating new rules, ensuring a clean restoration of existing statutes (Titles XIX and XI of the Social Security Act). This avoids potential challenges under administrative law by directly overriding the 2025 changes.
- Constitutional: No direct constitutional issues, as it pertains to Congress's spending and commerce powers over federal health programs; however, it could invite debates on federalism if states' Medicaid roles are affected.
- Political: The partisan short title ("Repealing the Trump Sick Tax Act") signals intent to reverse policies associated with a specific administration, potentially fueling debates on healthcare affordability, drug pricing, and government intervention in markets. If enacted, it could set a precedent for using reconciliation-like processes to undo prior fiscal laws.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (7)
Sen. Wyden, Ron [D-OR], Sen. Smith, Tina [D-MN], Sen. Luján, Ben Ray [D-NM], Sen. Van Hollen, Chris [D-MD], Sen. Sanders, Bernard [I-VT], Sen. Cortez Masto, Catherine [D-NV], Sen. Merkley, Jeff [D-OR]
Recent Actions
- 2025-07-24: Read twice and referred to the Committee on Finance.
- 2025-07-24: Introduced in Senate
Bill Versions
- Repealing the Trump Sick Tax Act — issued 2025-07-24 — PDF (2 pages)